Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Reviews Medicare Coverage With Evidence Development May 9

This article was originally published in The Pink Sheet Daily

Executive Summary

Open door forum will consider factors in providing Coverage with Evidence Development. Part B drugs are eligible for CED; comment deadline on CED draft guidance is June 6.

You may also be interested in...



House Appropriations Subcommittee Plans FDA Hearing July 26

Ag/FDA subcommittee had tabled FDA hearing pending confirmation of a permanent agency commissioner. House cleared FDA 2006 spending in early June.

Second Quarter Earnings Season Heats Up

Amgen, J&J, Sanofi-Aventis, Pfizer, Merck, Roche, Lilly and Schering-Plough are scheduled to report results in upcoming week. Bristol could expand upon plans to sell OTC unit to Novartis the following week.

Project BioShield Is Topic Of House Hearings July 12 And 14

Homeland Security/Emergency Preparedness Subcommittee and Government Reform Committee hearings will focus on countermeasure procurement issues and evaluating the effectiveness of the BioShield Act of 2004.

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel